Optimizing Denosumab Therapy in Rheumatic Diseases: Considerations for Disease Activity, Glucocorticoid Use, and Sequential Treatment

The Journal of Rheumatology 2026 Open access

Read full text
Authors: Yue Zhang, Jingqing Lin, Qi Zhong, Zhisheng Huang
DOI: 10.3899/jrheum.2025-0826
Cited by: 0
References: 7

Abstract

We read with great interest the article by Furukawa et al, titled "Long-Term Effectiveness and Safety of Denosumab for Osteoporosis in Patients With Rheumatic Diseases."1 The authors9 comprehensive evaluation of bone mineral density (BMD) changes over 7 years in patients with rheumatic diseases (RDs) provides critical insights into the long-term efficacy and safety of denosumab in this high-risk population.

Fields of Study & Subjects

Bone health and osteoporosis research Rheumatoid Arthritis Research and Therapies Bone health and treatments

Publication details

Journal / source
The Journal of Rheumatology
Volume
53
Issue
5
Pages
586–587
Publication date
15 March 2026
Language
EN